Join the Major Depressive Disorder group to help and get support from people like you.
Major Depressive Disorder News (Page 19)
Related terms: Clinical Depression, Unipolar Disorder, MDD
1 in 6 Patients Who Quit Antidepressants Get 'Discontinuation Symptoms'
FRIDAY, June 7, 2024 – Roughly 1 in 6 people who stop taking an antidepressant will experience symptoms caused by discontinuing the drug, a new review finds. However, only 1 in 35 will experience...
Many Patients Have Discontinuation Symptoms After Stopping Antidepressants
THURSDAY, June 6, 2024 – A considerable proportion of patients have discontinuation symptoms (e.g., dizziness, headache, nausea, insomnia, and irritability) after discontinuing antidepressants, ...
Coworker, Organizational Support Increase Nurses' Intent to Stay at Job
TUESDAY, June 4, 2024 – Coworker and employer support are strong predictors that nurses plan to stay in their jobs, according to a study published online May 31 in the Online Journal of Issues in ...
Night Owls Could Be Upping Their Mental Health Risks
FRIDAY, May 31, 2024 – People who regularly stay up until the wee hours of the morning could be harming their mental health, a new study finds. Regardless of whether people were morning larks or a...
Suicidal Impulses May Peak During Restless Nights
FRIDAY, May 31, 2024 – The wee hours of the morning could be the most dangerous for someone on the brink of suicide or homicide, a new study shows. There’s a five-fold greater risk for suicide and a...
Teens May Experience Delays in Bipolar Progression After Major Depressive Disorder
FRIDAY, May 31, 2024 – Adolescents may experience delayed bipolar disorder (BD) progression after major depressive disorder (MDD) diagnosis, according to a study published online May 29 in JAMA ...
Teen Smartphone Use Positively Tied to Mood
THURSDAY, May 30, 2024 – Adolescent smartphone use is positively associated with mood, according to a study published online May 29 in PLOS ONE. Matt Minich, Ph.D., and Megan Moreno, M.D., M.P.H., ...
Changes in Gender Identity Not Tied to Depressive Symptoms in Youth
WEDNESDAY, May 29, 2024 – Changes in gender identity are not associated with changes in depressive symptoms over time among sexual and gender minority (SGM) youth, according to a study published...
Early-Life Air, Noise Pollution Exposure Tied to Later Mental Health Issues
WEDNESDAY, May 29, 2024 – Early-life air and noise pollution exposure are prospectively associated with three common mental health problems from adolescence to young adulthood, according to a study...
Parental Legal System Involvement Linked to Adverse Child Mental Health
THURSDAY, May 23, 2024 – Parental legal system involvement may negatively impact child mental health, according to a study published online May 23 in Pediatrics. Lilian G. Bravo, Ph.D., R.N., from...
Recent Release From Jail a Big Risk Factor for Suicide
WEDNESDAY, May 15, 2024 – Inmates released from jail have a ninefold increased risk of suicide within the following year, compared to people who’ve never been incarcerated, new research shows. “...
GLP-1 Receptor Agonist Use Increases Likelihood of Antidepressant Prescription
WEDNESDAY, May 15, 2024 – Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a study published...
Virtual Reality Therapy Can Augment Depression Treatment
MONDAY, May 13, 2024 – Extended reality-enhanced behavioral activation (XR-BA) may be a feasible, noninferior, and acceptable enhancement to traditional BA for major depressive disorder (MDD),...
FDA Approves Exxua (gepirone) for the Treatment of Major Depressive Disorder in Adults
HOUSTON, Sept. 28, 2023 /PRNewswire/ – Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in psychiatry and...
U.S. FDA Approves Vraylar (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder
Approval marks fourth indication for Vraylar, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant...
Further information
Related condition support groups
Related drug support groups
Lexapro, Zoloft, sertraline, Wellbutrin, Cymbalta, trazodone, Prozac, Effexor, escitalopram, view more... bupropion, mirtazapine, Abilify, fluoxetine, venlafaxine, Paxil, Effexor XR, Pristiq, Wellbutrin XL, Viibryd, duloxetine, Trintellix, quetiapine, Remeron, Vraylar, paroxetine, Wellbutrin SR, olanzapine, Zyprexa, vortioxetine, aripiprazole, Seroquel XR, Rexulti, doxepin, Auvelity, desvenlafaxine